ChemDiv to Provide Schering Plough Corporation With Discovery Libraries in Multiyear Agreement

Friday, June 6, 2008 General News J E 4
SAN DIEGO, June 5 ChemDiv announced today the continuationof multi-year collaboration with Schering Plough Corporation. In the frameworkof this collaboration ChemDiv will provide Schering Plough with a set ofchemical libraries that will be produced through parallel synthesis based onthe customer selected templates. In accordance with the agreement teams ofChemDiv and Schering Plough scientists will work closely to develop exclusivesmall molecule libraries enhancing Schering Plough's global drug discoveryeffort. Further details and financial terms were not disclosed.

"ChemDiv is excited to be working with Schering Plough a pioneer ofpharmaceutical industry that is working to improve people's health and extendlives. Their decision to select ChemDiv as their drug discovery partnerunderscores the quality of our work, the innovation we bring to our partnersand our solid reputation for success in this field," said Nikolay Savchuk,President and CEO of ChemDiv. "We are committed to expanding our product lineto provide more integrated drug discovery services to our clients. We are nowengaged in more discovery research programs than ever before, and we lookforward to generating value on behalf of our clients."

About ChemDiv

ChemDiv Inc. (Chemical Diversity) is a global chemistry-driven contractresearch organization focused on identifying and delivering discoveryopportunities and services for life science partners, and merging industrialand academic efforts to bring new approaches to the treatment oflife-threatening diseases. For further information please visit

SOURCE ChemDiv Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
MacroChem Announces Presentation by Michael Zaslof...
GlaxoSmithKline Signs Licensing Agreement With Com...